Global Non-Insulin Therapies for Diabetes Market || 2021 Trends, Research Report, Growth Trends, Opportunities, Forecast to 2027

Non-insulin therapies are typically used in the treatment for type 2 diabetes patients, where patient’s body unable to produce sufficient insulin or body is incapable to use the insulin it produces. Non-insulin therapies have a different mechanism of action to maintain optimal glycemic control and to reduce blood glucose level. For instance, Sulfonylureas increase the insulin release from pancreatic cells and some agent like alpha-glucosidase inhibitors slow down the digestion of starch in the small intestine.

As of now, rising global incidence and prevalence of diabetes is anticipated to boost the global non-insulin therapies for diabetes market during the forecast period. For instance, according to the International Diabetes Federation’s (IDF), the global prevalence of diabetic accounted for around 425 million, among of 400 million people were suffering from type 2 disease in 2017. Thus, this data represents a high prevalence rate of diabetes across the world, which eventually demand proper treatment management. Therefore, it is expected to propel the global non-insulin therapies for diabetic market within the forecast period.

Download Free sample copy of this report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/55

The world’s economic burden of diabetes is huge and is projected to rise during the forecast period. As per the American Diabetes Association, the total budget of diagnosed diabetes has increased up to US$ 327 billion in 2017 from around US$ 245 billion in 2012. Henceforth, the global market for non-insulin therapies for diabetes is anticipated to fuel the growth over the forecast period.

However, the high cost of the novel class of drugs compared to conventional drugs may hamper the market growth over the forecast period.

The global non-insulin therapies for diabetes market is categorized on the basis of drug class, route of administration, distribution channel, and region.

The drug class segment includes Alpha-Glucosidase Inhibitors, Biguanides, and Sulfonylureas Thiazolidinedione’s, DPP-4 Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors.

Further, the global non-insulin therapies for diabetes market are segmented by route of administration, which includes oral and injectable.

On the basis of the distribution channel, the global non-insulin therapies for diabetes market is divided into retail pharmacy, hospital pharmacy, and online pharmacy.

On the basis of region, the target market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East and Africa. North America is projected to be the fastest growing region owing to the huge expenditure on diabetes treatment.

The key players operating in the global market of non-insulin therapies for diabetes include AstraZeneca, Bristol-Myers Squibb, BoehringerIngelheim GmbH, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Merck and Company, Janssen Pharmaceuticals, Novartis AG, Sanofi Aventis, Novo Nordisk, Pfizer and Takeda Pharmaceuticals.

Contact Us:
Mr Alex (Sales Manager)
Prophecy Market Insights
Phone: +91 777 504 9802
+1 860 531 2701
Email: sales@prophecymarketinsights.com

About us:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.

This release was published on openPR.